XML 37 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Cash flows from operating activities:      
Net loss $ (32,279,000) $ (32,451,000) $ (27,494,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 933,000 855,000 931,000
Amortization of deferred financing costs and debt discount 930,000 711,000 703,000
Increase in allowance for doubtful accounts 144,000 483,000 460,000
Change in fair value of warrants (209,000) (4,360,000) (1,285,000)
Change in fair value of option liability 340,000 740,000 30,000
Stock-based compensation 3,904,000 3,316,000 3,055,000
Equity loss from investment in joint venture 165,000 209,000 151,000
Increases (decreases) in cash caused by changes in operating assets and liabilities:      
Accounts receivable (1,810,000) (670,000) (902,000)
Inventories 143,000 60,000 (777,000)
Other current assets (324,000) (3,000) 36,000
Other assets (74,000) (1,206,000) (110,000)
Accounts payable and accrued expenses 1,183,000 (1,436,000) 811,000
Deferred revenues, related party (2,882,000) (1,992,000) (2,122,000)
Deferred revenues (2,609,000) 315,000 2,541,000
Long-term deferred rent 252,000 106,000 398,000
Net cash used in operating activities (32,193,000) (35,323,000) (23,574,000)
Cash flows from investing activities:      
Purchases of property and equipment (1,204,000) (560,000) (610,000)
Cash invested in restricted cash 0 0 (350,000)
Investment in joint venture 0 0 (330,000)
Net cash used in investing activities (1,204,000) (560,000) (1,290,000)
Cash flows from financing activities:      
Principal payments on long-term obligations (2,692,000) (4,529,000) (5,454,000)
Proceeds from long-term obligations 0 9,444,000 20,000,000
Debt issuance costs and loan fees 0 (719,000) (559,000)
Proceeds from exercise of employee stock options and warrants and stock purchase plan 1,413,000 2,849,000 7,128,000
Proceeds from sale of common stock 24,953,000 13,286,000 45,486,000
Costs from sale of common stock (1,482,000) (194,000) (1,923,000)
Net cash provided by financing activities 22,192,000 20,137,000 64,678,000
Net (decrease) increase in cash and cash equivalents (11,205,000) (15,746,000) 39,814,000
Cash and cash equivalents at beginning of year 36,922,000 52,668,000 12,854,000
Cash and cash equivalents at end of year 25,717,000 36,922,000 52,668,000
Cash paid during period for:      
Interest 2,497,000 2,031,000 1,226,000
Final payment fee on long-term debt 0 419,000 205,000
Supplemental schedule of non-cash investing and financing activities:      
Fair value of warrants allocated to additional paid-in capital 0 267,000 279,000
Additions to fixed assets included in accounts payable and accrued expenses 0 0 481,000
Capital equipment lease $ 0 $ 79,000 $ 0